Get 20M+ Full-Text Papers For Less Than $1.50/day. Subscribe now for You or Your Team.

Learn More →

Imatinib Mesylate as Add-on Therapy for Pulmonary Arterial Hypertension Results of the Randomized IMPRES Study

Imatinib Mesylate as Add-on Therapy for Pulmonary Arterial Hypertension Results of the Randomized... Hypertension Imatinib Mesylate as Add-on Therapy for Pulmonary Arterial Hypertension Results of the Randomized IMPRES Study Marius M. Hoeper, MD; Robyn J. Barst, MD; Robert C. Bourge, MD; Jeremy Feldman, MD; Adaani E. Frost, MD; Nazzareno Galié, MD; Miguel Angel Gómez-Sánchez, MD; Friedrich Grimminger, MD; Ekkehard Grünig, MD; Paul M. Hassoun, MD; Nicholas W. Morrell, MD; Andrew J. Peacock, MD; Toru Satoh, MD; Gérald Simonneau, MD; Victor F. Tapson, MD; Fernando Torres, MD; David Lawrence, PhD; Deborah A. Quinn, MD; Hossein-Ardeschir Ghofrani, MD Background—By its inhibitory effect on platelet-derived growth factor signaling, imatinib could be efficacious in treating patients with pulmonary arterial hypertension (PAH). Methods and Results—Imatinib in Pulmonary Arterial Hypertension, a Randomized, Efficacy Study (IMPRES), a randomized, double-blind, placebo-controlled 24-week trial, evaluated imatinib in patients with pulmonary vascular −5 resistance ≥800 dyne·s·cm symptomatic on ≥2 PAH therapies. The primary outcome was change in 6-minute walk distance. Secondary outcomes included changes in hemodynamics, functional class, serum levels of N-terminal brain natriuretic peptide, and time to clinical worsening. After completion of the core study, patients could enter an open- label long-term extension study. Of 202 patients enrolled, 41% patients received 3 PAH therapies, with the remainder on 2 therapies. After http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Circulation Wolters Kluwer Health

Imatinib Mesylate as Add-on Therapy for Pulmonary Arterial Hypertension Results of the Randomized IMPRES Study

Circulation , Volume 127 (10) – Mar 1, 2013

Loading next page...
 
/lp/wolters-kluwer-health/imatinib-mesylate-as-add-on-therapy-for-pulmonary-arterial-9mX328viHM

References (38)

Copyright
© 2013 American Heart Association, Inc.
ISSN
0009-7322
eISSN
1524-4539
DOI
10.1161/CIRCULATIONAHA.112.000765
pmid
23403476
Publisher site
See Article on Publisher Site

Abstract

Hypertension Imatinib Mesylate as Add-on Therapy for Pulmonary Arterial Hypertension Results of the Randomized IMPRES Study Marius M. Hoeper, MD; Robyn J. Barst, MD; Robert C. Bourge, MD; Jeremy Feldman, MD; Adaani E. Frost, MD; Nazzareno Galié, MD; Miguel Angel Gómez-Sánchez, MD; Friedrich Grimminger, MD; Ekkehard Grünig, MD; Paul M. Hassoun, MD; Nicholas W. Morrell, MD; Andrew J. Peacock, MD; Toru Satoh, MD; Gérald Simonneau, MD; Victor F. Tapson, MD; Fernando Torres, MD; David Lawrence, PhD; Deborah A. Quinn, MD; Hossein-Ardeschir Ghofrani, MD Background—By its inhibitory effect on platelet-derived growth factor signaling, imatinib could be efficacious in treating patients with pulmonary arterial hypertension (PAH). Methods and Results—Imatinib in Pulmonary Arterial Hypertension, a Randomized, Efficacy Study (IMPRES), a randomized, double-blind, placebo-controlled 24-week trial, evaluated imatinib in patients with pulmonary vascular −5 resistance ≥800 dyne·s·cm symptomatic on ≥2 PAH therapies. The primary outcome was change in 6-minute walk distance. Secondary outcomes included changes in hemodynamics, functional class, serum levels of N-terminal brain natriuretic peptide, and time to clinical worsening. After completion of the core study, patients could enter an open- label long-term extension study. Of 202 patients enrolled, 41% patients received 3 PAH therapies, with the remainder on 2 therapies. After

Journal

CirculationWolters Kluwer Health

Published: Mar 1, 2013

There are no references for this article.